Development
Thermo Fisher Scientific Inc.
TMO
$414.90
$0.17980.04%
NYSE
| 12/31/2023 | 09/30/2023 | 07/01/2023 | 04/01/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 6.00B | 5.94B | 5.72B | 6.02B | 6.95B |
| Total Depreciation and Amortization | 3.41B | 3.42B | 3.40B | 3.38B | 3.38B |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -458.00M | 32.00M | 148.00M | -17.00M | -128.00M |
| Change in Net Operating Assets | -537.00M | -1.22B | -1.58B | -1.71B | -1.05B |
| Cash from Operations | 8.41B | 8.17B | 7.69B | 7.68B | 9.15B |
| Capital Expenditure | -1.48B | -1.62B | -1.84B | -2.06B | -2.24B |
| Sale of Property, Plant, and Equipment | 87.00M | 82.00M | 20.00M | 28.00M | 24.00M |
| Cash Acquisitions | -3.66B | -3.66B | -2.75B | -2.70B | -39.00M |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -90.00M | -89.00M | -86.00M | 105.00M | 99.00M |
| Cash from Investing | -5.14B | -5.29B | -4.66B | -4.63B | -2.16B |
| Total Debt Issued | 7.56B | 8.57B | 5.31B | 5.12B | 4.72B |
| Total Debt Repaid | -7.72B | -3.94B | -2.64B | -2.95B | -4.07B |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -3.00B | -4.00B | -4.00B | -4.00B | -3.00B |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -523.00M | -504.00M | -487.00M | -469.00M | -455.00M |
| Other Financing Activities | 56.00M | 62.00M | 12.00M | 45.00M | -9.00M |
| Cash from Financing | -3.62B | 197.00M | -1.81B | -2.26B | -2.81B |
| Foreign Exchange rate Adjustments | -82.00M | 158.00M | 19.00M | -71.00M | -139.00M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -440.00M | 3.23B | 1.25B | 721.00M | 4.05B |